APOE and Alzheimer disease: AVAS treatment significantly increased MWM measures of memory and postsynaptic protein levels, indicating surrogate efficacy, reduced intracellular LDs, demonstrating indirect target engagement, and reduced pathological changes in Aβ solubility/deposition, and neuroinflammation, all critical components of APOE4-modulated AD pathology.